Teleflex Completes Enrollment in BIOMAG-LL Medical Device Study

Teleflex completed enrollment in a study evaluating 35 mm and 40 mm Freesolve resorbable magnesium scaffolds for de novo coronary lesions up to 38 mm. The primary endpoint is 12-month TLF, with follow-up through 60 months.